The PENTO Protocol in Medication-related Osteonecrosis of the Jaw
University Hospital, Limoges
17 participants
Feb 29, 2024
INTERVENTIONAL
Conditions
Summary
Medication-related osteonecrosis of the jaw (MRONJ) occurs after taking bisphosphonates or targeted therapies. It leads to a significant decrease in quality of life with pain, eating and chewing disorders, and malnutrition. Current treatments are only partially effective. PENTO (pentoxifylline and tocopherol) has been shown to be effective in maxillary osteoradionecrosis. The objective of this study is to evaluate the proportion of bone recovery in patients receiving PENTO in MRONJ at 12 months.
Eligibility
Inclusion Criteria5
- Age greater than or equal to 18 years
- Current or past treatment with bisphosphonates (oral or IV) and/or targeted therapies (denosumab, bevacizumab)
- Signs and symptoms for more than 8S with confirmation that the signs and symptoms are not of dental origin
- AAOMS Stage 2 MRONJ
- For patients of childbearing age, effective contraception is required
Exclusion Criteria17
- History of head or neck radiotherapy or maxilla metastases
- Patients who have received treatment in the past (PENTO or PENTOCLO protocol)
- Patients who have undergone surgery for their MRONJ within the last 3 months
- Pregnant or wishing to be pregnant, breastfeeding
- Patient under palliative care
- Patient with hypersensitivity to pentoxifylline or tocopherol or to an excipient
- History of hypersensitivity reaction to penicillins, cephalosporins, or other beta-lactams (and clindamycin or lincomycin if applicable) or excipient of amoxicillin-a. clavulanic or clindamycin
- History of jaundice/hepatic injury related to amoxicillin/clavulanic acid
- Patient taking oral anticoagulants, or with a history of major bleeding or bleeding disorders
- Patient taking platelet aggregation inhibitor, theophylline or aminophylline
- Patient taking methotrexate, probenecid, mycophenolate mofetil, myorelaxant drugs, macrolide or streptogramin antibiotics
- Patients with hepatic failure or renal failure (Cl < 30 mL/min),
- Patient with hypotension (SBP < 90 mmHg)
- Refusal to participate in the study
- Patient participating in other interventional research that may interfere with the conduct of this research
- Patient unable to understand the protocol
- Patient under curatorship or guardianship
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05795647